Global Landscape Analysis of Antibody-Drug Conjugate Clinical Trials for Prostate Cancer

A document analyzing the global landscape of antibody-drug conjugate (ADC) clinical trials for prostatic neoplasms. The study maps contemporary development patterns, identifies translational opportunities and gaps, and provides an integrated overview to support future clinical development. It was authored by Shuyu Ren and last updated on May 14, 2026.

Use Cases

• Mapping the global development landscape of ADCs for prostate cancer based on the described analysis of targets, payload classes, and endpoints.
• Identifying translational opportunities and gaps in ADC clinical translation based on the discussion of antigen heterogeneity and payload resistance.
• Supporting future clinical development strategy based on the integrated overview of current development patterns and sponsor types.

Strengths

• Focuses on a specific and high-interest therapeutic area: antibody-drug conjugates for prostate cancer.
• Provides an integrated overview intended to clarify fragmented development patterns across targets and sponsor types.
• Includes discussion of next-generation ADC programmes such as PSMA- and B7-H3-directed agents like MEDI3726 and DS-7300.

Limitations

• The dataset is a single 18.8 KB DOCX document, not a structured data table; row and column counts are unknown.
• Column-level documentation is absent; field semantics must be inferred after download.
• Freshness should be verified as the last update date is in the future (2026-05-14).

Provenance

Source

figshare

Collection Method

Likely a literature review and analysis of clinical trial registries.

Freshness

Last updated 2026-05-14 04:30:08

Geography

Global